REG - GSK PLC - Result of AGM

GSKAnnouncement

03/05/2023 18:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230503:nRSC3368Ya&default-theme=true

RNS Number : 3368Y  GSK PLC  03 May 2023

GSK plc

 

Results of 23rd Annual General Meeting

 

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on
Wednesday 3 May 2023 at the Sofitel Hotel in Terminal 5 Heathrow. Shareholders
were able to join the meeting in person or virtually via the Lumi AGM website.

 

All valid proxy votes (whether submitted electronically or in hard copy form)
were included in the poll taken at the meeting.

 

The table below shows the results of the poll on all 23 resolutions. The full
text of the resolutions is contained in the Notice of AGM published on 27
March 2023, which is available on GSK's website at www.gsk.com
(http://www.gsk.com) .

 

 Resolution                                                                           Total votes for((1)(2))  %      Total votes against((2))  %      Total votes cast  Votes withheld((3))
 1       Receive and adopt the 2022 Annual Report                                     2,838,286,554            99.05  27,282,840                0.95   2,865,569,394     11,463,434
 2       Approve the Annual report on remuneration                                    2,493,636,361            88.84  313,256,226               11.16  2,806,892,587     70,129,301
 3       Election of Julie Brown                                                      2,857,379,637            99.59  11,814,146                0.41   2,869,193,783     7,831,272
 4       Election of Dr Vishal Sikka                                                  2,860,647,976            99.69  8,837,033                 0.31   2,869,485,009     7,534,298
 5       Election of Elizabeth McKee Anderson                                         2,744,478,188            95.64  125,073,699               4.36   2,869,551,887     7,475,279
 6       Re-election of Sir Jonathan Symonds                                          2,774,824,580            96.72  94,170,389                3.28   2,868,994,969     8,020,637
 7       Re-election of Dame Emma Walmsley                                            2,862,165,104            99.74  7,358,771                 0.26   2,869,523,875     7,508,911
 8       Re-election of Charles Bancroft                                              2,786,237,098            97.24  79,167,334                2.76   2,865,404,432     11,602,033
 9       Re-election of Dr Hal Barron                                                 2,845,192,710            99.17  23,938,850                0.83   2,869,131,560     7,896,993
 10      Re-election of Dr Anne Beal                                                  2,788,179,755            97.17  81,326,824                2.83   2,869,506,579     7,517,274
 11      Re-election of Dr Harry C Dietz                                              2,863,558,514            99.83  4,932,171                 0.17   2,868,490,685     8,534,053
 12      Re-election of Dr Jesse Goodman                                              2,863,346,622            99.79  6,079,498                 0.21   2,869,426,120     7,596,197
 13      Re-election of Urs Rohner                                                    2,627,550,485            91.58  241,613,171               8.42   2,869,163,656     7,856,370
 14      Re-appointment of the auditor                                                2,846,403,783            99.86  4,095,644                 0.14   2,850,499,427     26,524,596
 15      Remuneration of the auditor                                                  2,865,552,679            99.83  4,889,379                 0.17   2,870,442,058     6,575,928
 16      Approve amendments to the Directors' Remuneration Policy                     2,837,886,999            99.01  28,431,513                0.99   2,866,318,512     10,705,019
 17      Authority for the company to make donations to political organisations and   2,778,351,786            98.69  36,846,645                1.31   2,815,198,431     61,881,372
         incur political expenditure
 18      Authority to allot shares                                                    2,749,592,663            95.85  118,984,091               4.15   2,868,576,754     8,438,938
 19      Disapplication of pre-emption rights - general power((4))                    2,774,457,577            96.79  91,974,467                3.21   2,866,432,044     10,561,299
 20      Disapplication of pre-emption rights - in connection with an acquisition or  2,747,347,831            95.84  119,258,296               4.16   2,866,606,127     10,393,035
         specified capital investment((4))
 21      Authority for the company to purchase its own shares((4))                    2,821,937,695            98.36  47,051,419                1.64   2,868,989,114     8,025,806
 22      Exemption from statement of senior statutory auditor's name                  2,856,668,700            99.67  9,373,459                 0.33   2,866,042,159     10,967,927
 23      Authority for reduced notice of a general meeting other than an AGM((4))     2,698,567,258            94.08  169,932,106               5.92   2,868,499,364     8,505,572

 

 

Notes:

 

(1)      The "for" votes include those giving the Chair discretion.

(2)      Votes "for" and "against" are expressed as a percentage of the
total votes cast.

(3)      A "vote withheld" is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a resolution.

(4)      Indicates Special Resolutions requiring a 75% majority of votes
cast.

 

The following table provides further information on participation in the AGM:

 

                                                                          GSK's 23(rd) AGM            GSK's 22(nd) AGM

                                                                          (Hybrid meeting)            (Hybrid meeting)

                                                                          (2023)                      (2022)
 Issued share capital (excluding Treasury Shares)                         4,094,980,743               5,083,974,547
 Total votes cast and votes withheld lodged as a % of GSK's issued share  70.26%                      70.25%
 capital (excluding Treasury Shares)
 Total shareholder population                                             63,362                      89,764
 Total number of proxies lodged                                           3,162                       5,343
 Number of shareholders in attendance                                     72 in person                93 in person

                                                                          49 participated virtually   68 participated virtually
 % of shareholders who lodged proxies                                     4.99%                       5.95%

 

The above poll results will shortly be available on the company's website at
www.gsk.com (http://www.gsk.com) .

 

In accordance with Listing Rule 9.6.2 of the Financial Conduct Authority's
(FCA) Listing Rules, a copy of the resolutions, other than those concerning
ordinary business, will be submitted to the FCA and will in due course be
available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

 

V A Whyte

Company Secretary

3 May 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAJMRTMTBMBPJ